Good morning, everyone, and welcome to the Medexus Pharmaceuticals Fourth Fiscal Quarter and 2024 Fiscal Year Conference Call. At this time, all participants are in a listen-only mode, and we will be opening for questions following the presentation. If anyone should require operator assistance during the conference, please press star zero on your phone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Victoria Rutherford, Investor Relations at Medexus. Over to you. Thank you, and good morning, everyone. Welcome to the Medexus Pharmaceuticals Fourth Quarter and Fiscal 2024 Earnings Call. On the call this morning are Ken d’Entremont, Chief Executive Officer, and Marcel Konrad, Chief Financial Officer. If you have any additional questions after the conference call or would like further information about the company, please contact us at 480-625-5772. I would like to remind everyone that this discussion will include forward-looking information as defined in securities laws. Actual results may differ materially from historical results or results anticipated by the forward-looking information. In addition, this discussion will also include non-GAAP measures such as adjusted net income and loss and adjusted EBITDA, which do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. For more information about forward-looking information and non-GAAP measures, including reconciliations to net income and loss, please refer to the company's MD&A, which, along with the financial statements, are available on the company's website at www.medexus.com and on SEDAR+ at www.sedarplus.ca. As a reminder, Medexus reports on March 31st fiscal year basis. Medexus reports financial results in U.S. dollars. I would now like to turn the call over to Ken d’Entremont. Thank you, Victoria, and thank you to everyone for joining the call today. We are proud of the financial results we're reporting for fiscal year 2024. We believe we achieved both record revenues of USD 113.1 million and record adjusted EBITDA of USD 19.5 million for fiscal year 2024, together with solid operating income of USD 10.8 million and a modest net loss of USD 0.02 million. We responded swiftly to the adverse trends affecting our business, and we are pleased with the initial progress of our ongoing expense management initiative, which is reflected in our financial results for fiscal Q4 2024. Before I go into detail on our base business, I will provide some color on a positive development in the regulatory process for treosulfan, a key pipeline opportunity for Medexus. Earlier this month, we were informed by Medac, our licensor, for treosulfan that the FDA had accepted for review Medac's April 2024 resubmission of the new drug application for treosulfan. We expect that the FDA will complete its review and issue a decision by October 30th of this year. We remain optimistic about the prospect of a treosulfan approval in the U.S. and about treosulfan's potential in the U.S. market because we continue to believe that treosulfan would prove to be the gold standard in this therapeutic space, as it has in Europe and in Canada. If approved by the FDA, we expect that treosulfan would have a meaningful impact on Medexus's total revenue. Given this positive development and the revenue opportunity for this product represents, we intend to begin making judicious investments in personnel to make sure we can hit the ground running if and when approved. That being said, we would not expect significant revenue from treosulfan until early fiscal year 2026, being the second quarter of next year at the earliest. As a reminder, under the terms of our amended U.S. license agreement for treosulfan, we are now in a negotiation period to agree with Medac on any adjustments to unpaid milestones, including those that would become payable following approval. These negotiations could result in adjustments to the amount and/or timing of these payments. To be clear, we are under no obligation to make any milestone payments before the effective date of any such amendment. In the meantime, we are pleased with the performance of our base business this quarter, despite some headwinds. Our fiscal Q4 2024 revenue of USD 26 million decreased by USD 2.6 million compared to Q4 2023, or a 9.1% decrease year-over-year. Adjusted EBITDA of USD 4.4 million for the quarter was a decrease compared to USD 4.8 million for the same period last year. We produced net income of USD 0.8 million for the quarter, a decrease compared to net income of USD 6.9 million for the same period last year, and a positive operating income of USD 0.8 million, a decrease compared to USD 2.7 million for the same period last year. Turning to our specific products, IXINITY unit demand decreased by 6% over the trailing 12-month period ending March 31st, 2024. We now believe that a challenging demand environment, together with anticipated impact of the U.S. Inflation Reduction Act, will impact product-level revenue going forward. We will continue to maintain existing demand, bolstered by our now-approved pediatric indication as a tailwind, but we have reduced investments in growth. On Rasuvo, we maintain a market-leading position during the quarter as unit demand remains strong. We continue to see the increased impact of product-level revenue attributable to government-sponsored programs. This impacts product-level revenue as these programs benefit from statutory discounts and rebates, including under the U.S. Inflation Reduction Act. Rupall unit demand increased by 21% over the trailing 12-month period ended March 31st, 2024. We expect that following the end of the product's market exclusivity period in January 2025, Rupall will face generic competition in Canada. As is typical in such situations, generic competition will likely prompt us to execute effective unit-level price reductions. We continue to see topical terbinafine, which we licensed in March 2023, as a strategic fit with Rupall. Health Canada's commitment to review our topical terbinafine new drug submission, submitted in December 2023, brings us a step closer to making the product a viable treatment option for fungal nail infections in Canada and is consistent with our plans to target commercial launch in the first half of calendar 2025. If and when approved, this product will enter a market that we estimate to be USD 88 million on an annual basis. On Gleolan, we continue seeking to maximize product-level revenue. Although Gleolan's performance in the U.S. has remained lower than expected, unit demand has been growing moderately over the course of fiscal 2024 as new customers adopt the product. Metoject unit demand in Canada increased by 13% in the trailing 12-month period ending March 31st, 2024. Following a trial in January 2023, Canada's Federal Court declined to uphold the Canadian patent for Metoject, which we sought to defend in response to the at-risk launch of a generic version of Metoject. While this outcome has disappointed, we previously adjusted our commercial strategy, and so we expect this outcome to have limited impact on the company and the product. In sum, we continue to focus on maintaining stability in our base business and generating cash from operations as we prepare for the revenue opportunities presented by our pipeline products. I will continue with some updates on our leadership team. With the successful completion of fiscal year 2024, Marcel Conrad, who has served as our CFO since June 2021, has chosen to depart Medexus to pursue other opportunities. Marcel's last day will be this Friday, June 28th. For our long-standing succession plan, we have appointed Brendon Bushman, who joined Medexus in June 2019 and has worked closely with Marcel through Marcel's entire tenure to step into the CFO role. Among other great qualifications, Brendon has extensive experience building and leading finance and accounting teams through periods of rapid growth, which continues to be our objective for Medexus. I look forward to continuing to work with Brendon in his new capacity. I'd also like to thank Marcel for his years of service on the Medexus senior management team. I wish him all the best in his future endeavors. In addition, effective Monday, June 24th, we appointed Richard Lebel as our Chief Operating Officer. Richard will now oversee all day-to-day business operations across Canada and the United States and ensure they align with our strategic goals. This expanded role builds on his demonstrated success in leading Canada's Canadian operations, among other things. Also effective Monday, Mike Adelman, who has been an important part of the Medexus team since joining as part of our IXINITY acquisition, has departed the company. My congratulations to Richard on this expanded role, and I'd like to thank Mike for his extensive service to Medexus. I and the rest of the Medexus team wish him all the best. To wrap up this update, I'm confident there will be a seamless transition in the CFO role and that this strategic reorganization will ensure our ability to embark on the next chapter of Medexus' growth story. I will now turn the call over to Marcel, who, one last time, will discuss our financial results in more detail. Marcel? Yes. Thank you. Thank you very much, Ken. I've been really fortunate to be part of a great Medexus journey to become a leading North America-based specialty pharma company. And now I believe we have a solid foundation to build upon, and I very much look forward to following Brendon's and Medexus' future successes with great interest. We're pleased to report our eighth consecutive quarter of positive operating income and tenth consecutive quarter of positive adjusted EBITDA. Turning to the full quarterly results, total revenue for the fiscal fourth quarter was USD 26 million. This quarterly revenue number represents a decrease of USD 2.6 million compared to USD 28.6 million for the three-month period ended March 31st, 2023. Total revenue for the full year was USD 113.1 million, reflecting a USD 5 million, or 4.6%, improvement compared to USD 108.1 million for fiscal year 2023. This decrease in fourth quarter revenue is primarily attributable to trends affecting IXINITY and Rasuvo. Specifically, IXINITY revenue in the second half of fiscal year 2024 was affected by lower-than-expected purchases by pharmacy and wholesale customers relative to a decrease in patient unit demand, which Medexus believes is a result of those customers working through inventory on hand and the accumulating effect of continued effective unit-level price reductions for Rasuvo. Gross profit was USD 13.3 million and USD 59.5 million for the three and 12-month periods ended March 31st, 2024, respectively, compared to gross profit of USD 15 million and USD 60 million for the same period in the previous year. The gross margin was 51.2% and 52.6% for the three and 12-month periods ended March 31st, 2024, respectively, compared to 52.5% and 55.5% for the three and 12-month period ended March 31st, 2023. The $0.5 million year-over-year decrease in gross profit and 2.9 percentage point year-over-year decrease in gross margin primarily reflect changes in the relative contribution of product-level net sales, including the effect of Gleolan sales in the United States before September 2022 and the accumulating effect of continued effective unit-level price reductions for Rasuvo. Selling and administrative expenses were $10.3 million and $44.9 million for the three and 12-month periods ended March 31st, 2024, compared to $11.4 million and $48.3 million for the three and 12-month periods ended March 31st, 2023. The $3.4 million year-over-year decrease in selling and administrative expense was primarily attributable to reductions in operating expenses, including as a continuing effort of cost reduction initiatives implemented in October 2022 and January 2024. In both cases, we have responded quickly to trends affecting our business. The January 2024 cost reduction initiative involved a reduction in Medexus' allocation of sales force resources to IXINITY and Rasuvo, which the company expects will improve the contributions of those products to overall financial results. Medexus intends to seek and consider efficient approaches to allocating its remaining sales force resources to its products based on the company's strategic plan. Research and development was USD 0.1 million and USD 1.6 million for the three and 12-month periods ended March 31st, 2024. This compares to USD 0.7 million and USD 2.9 million for the three and 12-month periods ended March 31st, 2023. Adjusted EBITDA for the three and 12-month periods ended March 31st, 2024 was positive USD 4.4 million and USD 19.5 million compared to USD 4.8 million and USD 16 million for the three and 12-month periods ended March 31st, 2023. The full-year USD 3.4 million increase in adjusted EBITDA was primarily attributable to the year-over-year changes in revenue together with reductions in operating expenses over fiscal year 2024. The net income for the 3- and 12-month periods ended March 31st, 2024 was USD 0.8 million and negative USD 0.2 million compared to net income of USD 6.9 million and USD 1.2 million for the same period last year. Net income or loss includes a non-cash unrealized gain or loss on fair value of the embedded derivatives in our now retired convertible debentures, which were sensitive to, among other things, fluctuations in our share price. As such, we believe that adjusted net income or loss has historically provided a better representation of performance of our operations because it excludes these non-cash fair value adjustments on liabilities. Our adjusted net income for the 3- and 12-month periods ended March 31st, 2024 was USD 0.8 million and negative USD 0.3 million compared to an adjusted net income of USD 6 million and negative USD 1.3 million for the same period last year. Our available liquidity, consisting of cash and cash equivalents, stands at USD 5.3 million at March 31st, 2024. The primary factor in the year-over-year net decrease in cash as compared to March 31st, 2023, was Medexus' use of cash to make the final maturity date payment in respect of the company's now repaid convertible debentures in October 2023, partially offset by, among other things, cash provided by operating activities of USD 18.7 million for fiscal year 2024. The repayment of our convertible debentures fully in cash in October 2023 has simplified our balance sheet and eased our BMO credit facilities, which continue to benefit from an attractive interest rate as our only remaining debt. As of March 31st, 2024, we had a combined USD 51.7 million outstanding on those facilities, which we will continue to pay down over the term. Together with strong cash provided by operating activities in both fiscal year 2024 and fiscal Q4 2024, we believe we are on solid footing to continue maintaining and growing our business over the coming quarters. As always, there can be variability in quarter-to-quarter results, but we look forward and are energized to continue to build the company and its portfolio in the coming quarters and beyond. Operator, we will now open the call to questions. Thank you very much. We are now opening the floor for your questions. If you have any questions, please press star one on your phone keypad now. We ask that while you're posing your question, you please pick up your handset if you are listening on a speakerphone to provide optimum sound quality. Please wait a moment whilst we poll for questions. Thank you. Your first question is coming from Andre Uddin of Research Capital. Andre, your line is live. Good morning, Ken and Marcel. Could you just elaborate a little bit more in terms of the market dynamics for IXINITY and Rasuvo in terms of pricing and competition? That would be great. Thanks. Sure. I'll take a crack at that. So, as we've said in previous quarters, we are seeing reductions in gross-to-net on Rasuvo as more and more pricing controls come into play in the U.S. And so we have seen that being decreasing over the quarters. So it's kind of offsetting the increase in unit growth that we are getting and continue to get. On IXINITY, a slightly different dynamic in that the demand has flattened and is slightly decreasing. So patients aren't filling at exactly the same rate as they have historically. And so that clearly has an impact. So those are the two dynamics there. Gleolan appears to be unaffected at this point. That's great. And just it was also nice to see treosulfan advancing forward with the FDA. Just looking ahead also in terms of triamcinolone, what do you actually need to do to get that FDA approved? And are you looking at that one? Yes, we are looking at that one. Triamcinolone is a slightly different issue in that its availability of the product that is the challenge is there are very few sources of it, yet it's a drug of choice for juvenile idiopathic arthritis. It has been a challenge to have it manufactured. Once that is resolved, then yeah, we would seek to pursue an FDA approval. We have not initiated that yet. Just one last question. About how many sales reps would you need for treosulfan in the U.S.? Yeah, we're in the midst of reevaluating the launch plan, so I'm not going to give a specific number, but it's relatively small. As we've discussed before, the number of institutions that do stem cell transplants in the U.S. is very limited. So it's a relatively small number, but we haven't finalized the launch plan. We're in the process of reevaluating that whole plan. Great. Thanks, Ken. Thank you very much. Your next question is coming from Rahul Sarugaser of Raymond James. Rahul, your line is live. Hi, Ken. Hi, Marcel. This is Mike on for Rahul today. I guess following on to Andre's question there, I wonder if you could discuss, I guess, your initial ideas on process and timelines around a potential treosulfan launch, assuming the drug is approved. What sort of investments would you be making prior to October, as you alluded to? And then how might you be investing after a potential approval? Yeah. Thanks, Mike. Great question. So as we put in this report, we are making some modest investments in treosulfan now. We are adding some people in the field, so MSLs, which will allow us to get prepared for the eventual launch, assuming a positive decision in October. Post-October, we would then execute the commercial plan. And again, it's relatively modest spending for the significance of the opportunity that we see because it's mostly medically driven. Obviously, it's a deeply scientific area. And we would invest in personnel and programs that would share that science and experience that's been developed in other markets with the American transplanters. Very good. Thank you. And I guess my second question will be on IXINITY. How do you see the recent pediatric approval factoring into the structural issues that you're encountering in the hemophilia B market? Is there any possibility that this could make the drug more durable in this environment, or are sort of the prevailing winds a bit too strong for that? Yeah, it's a great question. And we're in the midst of evaluating that as we are gaining experience with the now approved pediatric indications. So what we have found recently is that we are getting pediatric patients. It's a familial disease, so there could be several individuals in the same family that would have the condition. So having pediatric indication when there's multiple children, some of which may be under 12, makes it easier for the family, the parent, whoever's doing the infusion, just to have one drug product in the house rather than several. It also helps us in contracting. So as we work with our customers, there may be the opportunity to have various contracts, and having full indication gives us a much stronger position. So I guess in sum, we are looking at the impact of the pediatric indication. Thus far, it's been positive. We'll see what that does to the trajectory of the drug going forward. All right. Thank you, guys. I'll leave it there. Thank you very much. Your next question is coming from David Martin of Bloom Burton. David, your line is live. Good morning, Ken and Marcel. Also on IXINITY, just want to clarify. When you say unit demand decreased 6% year-over-year in the 2024 fiscal year, is that at the level of the patient, or is that the level of the units that Medexus shipped? That's a great question, David. Both are down. And as we've said before, we are trying to balance patient demand with units we ship. I think the 6, and correct me if I'm wrong, Marcel, but I think the 6 that we referenced is units we shipped. Yeah, it's demand. So it's demand year-over-year, yeah. Unit demand levels. Okay. And what was the decrease in fiscal fourth quarter? Marcel, do you have that number? I'm sorry, David. What was your question? What was the decrease in IXINITY unit demand in fiscal fourth quarter year-over-year? That is essentially based on a 12-month trailing basis, yeah. What we give now for the quarter is on a 12-month trailing basis, so not on a quarter-by-quarter, yeah. I don't think we have given that in. Okay. So you've got unit demand at the patient level going down, and there's also inventory drawdown at the pharmacies and wholesalers. When do you expect that inventory drawdown to end? And when it does, where do you think the trajectory of your net sales is going to go on the product? I can give some general comments on that. We're not giving guidance on product-level revenue, nor for the company. The drawdown on inventory in the channel, we think will be modest over the coming quarters. It hasn't built to a level that is unsustainable, so it's not that big an issue. We do want patient demand, so actual consumption use in the market, to be more closely related to customer demand, meaning specialty pharmacies. When that's balanced, we're satisfied if the month on hand is in a regular normal range. We're heading towards that. I don't think we're going to see any dramatic changes quarter to quarter. We're slowly moving towards what we think is a proper balance. Okay. Your OpEx, you've got some reductions to the IXINITY and Rasuvo infrastructure, but you're also building for treosulfan. Should we look at overall OpEx being relatively stable with fiscal Q4? Yeah, relatively stable. So the investment in IXINITY is really an investment between here and October. And then we'll see what the decision is at the end of October. So it's a modest increase. We'll fund that from within the current budget. We can do that as we've got savings elsewhere. So I don't think you're going to see any dramatic change. Okay. And then the last question. There was quite a drop in the cash from fiscal Q3 to fiscal Q4. You made that maturity payment in October. What was the consumption of the cash between these two in the fourth quarter? I'll let Marcel pick that one up. Yeah. Thanks for the question, David. Yeah, you've seen that drop from we had, I think, over $8 million. Now we're with over $5 million. We've made that payment in October, you're right. So all these sort of cash levels are planned as they shake out. We have made in Q4 specifically, as you mentioned, the drop versus Q3. There's some payments that we've made, for example, on the inventory side. There's some royalty payments in there. So I would say these are quarterly fluctuations that we are dissipating. We are also coming out from a Q3 quarter that was a little bit softer, as you remember. So we sort of recovered that in Q4. And really, so these are normal fluctuations which we're planning. We're monitoring our liquidity, of course, very, very closely. So nothing else to point out there at this point, yeah. Okay. That's it for me. Thanks. Thank you very much. Your next question is coming from Christopher Pugh of Canaccord Genuity. Christopher, your line is live. Yeah, thanks. Good morning. I'm calling in for Tania. I just had a quick question on the Gleolan, in that the orphan drug exclusivity, I believe, is expiring or it has expired recently this month. I'm just wondering, what's your outlook on potential generic competition in that space? Yeah, that's a great question. So you are correct. It has just expired or is shortly expiring. So we don't expect to see any competition. There's nothing on the horizon. We would be aware of it if there were something close. And so unlikely to see anything in the next 12-18 months, if at all. The situation in other markets is there is no generic. So exclusivity is long expired in the European markets, and there's also no generic there. It's our belief that the volume is relatively small, given the rare disease status of glioblastoma. And so any price reductions would make a generic unviable. So it hasn't occurred in other markets. We don't foresee it in the near future in the U.S. either. Okay. That's great. Yeah, I'll jump back. Thanks. Thank you very much. If anyone has any remaining questions, you can press star one on your phone keypad now to join the queue. Thank you. Your next question is coming from Stefan Quenneville of Ventum Capital Markets. Stefan, your line is live. Thanks for taking my questions, guys. Just a quick question on some of the operational changes you've talked about. With the head of Canadian operations sort of taking over as the COO, I was just curious if any of the learnings on treosulfan's, I think, successful launch in Canada, obviously, it's a different market than the U.S., but is there anything you can glean from that to make sure the drug launches well in the U.S.? And sort of what you've learned from your experience in Canada? Yeah. Stefan, great question. That is specifically one of the reasons why we've made this move, in that Richard and the person who leads this franchise in Canada have developed good understanding, deep understanding of what it takes to execute a successful launch on treosulfan. Obviously, the markets are different, but the clinical practice isn't different in the two countries. So that will certainly help, and we'll bring that experience to the US launch. And then, clearly, using all the excellent US experience people that we already have in place working with Richard, we think that the team together will be able to execute a successful launch because we'll transplant the experience from Canada to the US and have the US experience in place. Okay. And then just a question on and I think people have touched on this, so I'm just going to try and get a little more precision. So I'll ask the question for maybe a third time. In terms of hiring for Treo and also your kind of guidance that you're not going to see meaningful revenue for Treo until about Q2 of 2025, is that because you're going to wait to hear about approval in end of October before you bring on those extra salespeople? And like you said, you're doing it a little bit ahead of that, but the bulk of those hires are going to come subsequent to the potential approval? Correct. So we will start with the MSLs very shortly. We already have some people in place who are working in the field, but we'll be adding some MSLs prior to the decision date, so somewhat at risk. And then we will hire the remaining individuals upon the decision, positive decision, and then execute the launch. There is a lag time between decision and having product available. So that's part of the thinking as well, that there's no point having a whole bunch of salespeople in place without product available. So we'll be looking to condense the product availability as much as possible and then having those people in field as soon after the launch as possible when they can start to commercialize. Okay. Great. And just one last one. Just in terms of, I don't know if you're going to maybe a quarterly or annual target in terms of using your cash flow to pay down debt. Are you guys, can you share your thoughts on that over, say, the next 12 months and what kind of USDence you're looking to pay down at? Yeah. I'll turn it over to Marcel. But as he said, we've been paying down the BMO debt since it was put in place, and we'll continue to pay it down. And the schedule has been published, but I'll turn it over to Marcel to give you the details. Yeah. Correct. Thanks, Ken. Yes. Stefan, that's exactly it. Yeah. We started out with 56.5 million of the total facility, and now we're down to over $51 million. We have an amortization schedule that we're going to stick to in terms of the payment. That translates into a quarterly payment of about $3.3 million per quarter going forward to pay down the debt. That's great. Thanks, guys. That's it for me. Thank you very much. Your next question is coming from Julian Hung of Stifel. Julian, your line is live. Hi. This is Julian subbing in for Justin today. I was hoping to get a refresher on treosulfan estimates. What do the peak sales expectations look like? How soon do you expect to reach that number, and what would the ramp-up look like? Yeah. Thanks, Julian. A good question. I think what we can say about that is, obviously, we've got a forecast and experience with it now in Canada and what the ramp looks like from this territory. And I think the guidance that we've given is a factual statement, which is the historical busulfan peak sales, which was USD 126 million, which they achieved. I think it was 2016 or 2018, something like that. So there's been some price appreciation since then. So that's kind of guidance. I've said we see it over USD 100 million, but we haven't given any specific number. The ramp to peak, obviously, is dependent on the clinical package and data that's available. I think in this case, it's a bit of a unique situation in that there's ample clinical evidence of the utility of this drug in many different indications, including the two key ones, which would be AML and MDS, the two biggest reasons for allotransplants. And so I think the clinical experience is deep in other territories. So the task for us is to transport that experience from other markets to the U.S. market and give those U.S. transplanters some experience with the drug, which we think they will adopt relatively quickly. Thank you so much for taking my question. Thank you very much. Well, that appears to be the end of our question and answer session. I will now turn the call back over to the management for any closing remarks. Just want to thank everybody for joining us on the call today. We look forward to keeping you informed of our progress with our base business as well as the regulatory file on treosulfan. Thanks very much. Thank you very much. This does conclude today's conference. You may now disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.